日本神経治療学会が目指すもの

抄録

I have been appointed as the new president, succeeding Dr. Satoshi Kuwahara, from the 42nd Annual Meeting of the Japanese Society of Neurological Therapeutics (Makuhari Messe) in November 2024. The Society's predecessor, the Neurological Therapeutics Research Group, was established in 1983, when there were still few treatments for neurological disorders, with the aim of spreading knowledge about treatment and providing the best treatment available at the time in daily clinical practice. The Society was established in 1992 with the aim of promoting the development of therapeutics, education and awareness, and the development of new treatments, with a focus on the treatment of neurological disorders.

Here, I will introduce the activities of two representative committees. The Internationalization Committee aims to promote the Society's international collaboration and to share the latest knowledge with the Japanese community. As mentioned above, since 2010, we have been sending members to the ASENT Annual Meeting in the United States, and we planned a special lecture at the Society's academic conference in 2011. Since then, we have held a JSNT–ASENT joint symposium at ASENT, further deepening our relationship.

The Drug Discovery Promotion Committee aims to accelerate innovative drug discovery in the field of neurology through collaboration between industry, government, and academia, and to act as a bridge from seeds to practical application through clinical trial support and clinical development advice. In addition to posting information on clinical trials supported by the society on its website, the committee also works on providing clinical trial facility surveys at the request of companies for clinical trials where it is difficult to enroll subjects due to rare diseases, etc. (clinical trial support project).